ExAblate® O.R. is a new treatment modality that combines the non-invasive capabilities of Focused Ultrasound with the precision of Magnetic Resonance Imaging . ExAblate's MRgFUS technology enables precision ablatement of target tissue without surgical intervention.
ExAblate O.R. is the first and only commercially approved MR guided Focused Ultrasound treatment for Uterine Fibroids and for Adenomyosis.
ExAblate O.R. now offers a non-ionizing radiation treatment alternative for Pain Palliation of Bone Metastases or benign tumors such as Osteoid Osteoma
ExAblate's innovative, industry-transforming technology has earned numerous awards and honors.
ExAblate O.R - offering patients the latest in non-invasive treatment options, and physicians the state-of-the-art advantage for their practices,
ExAblate O.R. Benefits
Safe, non-invasive therapies
State-of-the-art technology that patients demand
Clinically proven in thousands of patients and hundreds of peer-reviewed papers
Consistent, predictable and immediate results
Few to no side effects
Quick recovery time
No incisions or general anesthesia
No hospital stay – fast return to normal life
"…providing a noninvasive focused treatment requiring minimal hospitalization, preparation and after-care, (MRgFUS) satisfies health economists and patients."
EA Dick and WMW Gedroyc. Expert Rev. Med. Devices 7(5), 2010.
* Not all applications are approved in all regions. Please consult your local representatives and read the product labeling specific for your region to determine approved indications for use.
For more information please contact us